Efficacy and Safety of Pembrolizumab Combined with Albumin-Bound Paclitaxel and Nedaplatin for Advanced Esophageal Squamous Cell Carcinoma

References

• Sung H , Ferlay J , Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Zheng RS , Zhang SW , Zeng HM et al. Cancer incidence and mortality in China, 2016. J. Natl. Cancer Center 2(1), 1–9 (2022).
   Google Scholar
• Yang H , Li X , Yang W . Advances in targeted therapy and immunotherapy for esophageal cancer. Chin. Med. J. (Engl.) 136(16), 1910–1922 (2023).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network . NCCN Guidelines in esophageal and esophagogastric junction cancers, version 3 (2023). www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf
   Google Scholar
• Zhao J , Zhang S , Guo X et al. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis. BMC Cancer 23(1), 1221 (2023).
   PubMed Web of Science ®Google Scholar
• Pembrolizumab Injection (Keytruda) instruction . China, Approval: 2018-07-20, Update: 2023-09-05. www.msdchina.com.cn/Product
   Google Scholar
• Sun JM , Shen L , Shah MA et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced esophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398(10302), 759–771 (2021).
   PubMed Web of Science ®Google Scholar
• Metges JP , Kato K , Sun JM et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. American Society of Clinical Oncology-Gastrointestinal Cancers Symposium, CA, USA, Abstract #241 (2022).
   Google Scholar
• Li Z , Sun Y , Ye F et al. First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590. American Society of Clinical Oncology, IL, USA, Abstract #4049 (2021).
   Google Scholar
• Luo H , Lu J , Bai Y et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA 326(10), 916–925 (2021).
   PubMed Web of Science ®Google Scholar
• Lu ZH , Wang JY , Shu YQ et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic esophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377, e068714 (2022).
   PubMedGoogle Scholar
• Wang ZX , Cui CX , Yao J et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40(3), 277–288 (2022).
   PubMed Web of Science ®Google Scholar
• Xu J , Kato K , Raymond E et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 24(5), 483–495 (2023).
   PubMed Web of Science ®Google Scholar
• Xin D , Song Y , Mu L et al. The efficacy and safety of nanoparticle albumin bound-paclitaxel-based regimen as second- or third-line treatment in patients with advanced esophageal squamous cell carcinoma. Thorac. Cancer 14(15), 1392–1397 (2023).
   PubMed Web of Science ®Google Scholar
• Wang HY , Yao ZH , Tang H et al. Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco. Targets Ther. 30(9), 5663–5669 (2016).
   Google Scholar
• Zhang F , Wang Y , Wang ZQ et al. Efficacy and safety of cisplatin-based versus nedaplatin-based regimens for the treatment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis. Dis. Esophagus 30(2), 1–8 (2017).
   Web of Science ®Google Scholar
• Fang Y , Mingzhen Y , Longpei C et al. Clinical observation of albumin-bound paclitaxel plus nedaplatin as first-line treatment in advanced esophageal squamous cell carcinoma patients. Chin. Oncol. 30(8), 632–635 (2020).
   Google Scholar
• Chen Y , Ye J , Zhu Z et al. Comparing paclitaxel plus fluorouracil versus cisplatin plus fluorouracil in chemoradiotherapy for locally advanced esophageal squamous cell cancer: a randomized, multicenter, phase III clinical trial. J. Clin. Oncol. 37(20), 1695–1703 (2019).
   PubMed Web of Science ®Google Scholar
• Yan F , Ying M , Chen L , Fu Q et al. Efficacy and safety of pembrolizumab plus albumin-bound paclitaxel and nedaplatin as a first-line therapy for advanced esophageal squamous cell carcinoma. Chin. J. Cancer Biother. 29(9), 801–806 (2022).
   Google Scholar
• Eisenhauer EA , Therasse P , Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Schwartz LH , Litière S , de Vries E et al. RECIST 1.1 – update and clarification: from the RECIST Committee. Eur. J. Cancer 62, 132–137 (2016).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute Common Toxicity Criteria (version 5.0). https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf
   Google Scholar
• Xia P , Li P , Wu S et al. Evaluation of the safety and effectiveness of neoadjuvant combined chemoimmunotherapy in the treatment of locally advanced esophageal squamous cell carcinoma: a retrospective single-arm cohort study. Ann. Transl. Med. 10(18), 991 (2022).
   PubMed Web of Science ®Google Scholar
• Xu J , Bai Y , Li E , Xu N , Shi D , Qian J . Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review. Expert Rev. Anticancer Ther. 22(9), 981–998 (2022).
   PubMed Web of Science ®Google Scholar
• Li Y , Zhou A , Liu S , He M et al. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized phase II clinical trial: a randomized clinical trial of neoadjuvant therapy for ESCC. BMC Med. 21(1), 86 (2023).
   PubMed Web of Science ®Google Scholar
• Hirano H , Kato K . Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J. Clin. Oncol. 49(5), 412–420 (2019).
   PubMed Web of Science ®Google Scholar
• Osman MA , Elkady MS , Nasr KE . Weekly paclitaxel versus three-weekly paclitaxel in recurrent platinum-resistant epithelial ovarian and peritoneal cancers: a phase III study. Clin. Med. Insights Oncol. 10, 35–41 (2016).
   PubMed Web of Science ®Google Scholar
• Dalton HJ , Yu X , Hu L et al. An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer. Gynecol. Oncol. 124(2), 199–204 (2012).
   PubMed Web of Science ®Google Scholar
• Kojima T , Shah MA , Muro K et al. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J. Clin. Oncol. 38(35), 4138–4148 (2020).
   PubMed Web of Science ®Google Scholar
• Shapiro J , van Lanschot JJB , Hulshof MCCM et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 16(9), 1090–1098 (2015).
   PubMed Web of Science ®Google Scholar
• Yang H , Liu H , Chen Y et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 156(8), 721–729 (2021).
   PubMed Web of Science ®Google Scholar
• Klevebro F , Alexandersson von Döbeln G , Wang N et al. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann. Oncol. 27, 660–667 (2016).
   PubMed Web of Science ®Google Scholar
• Fan Y , Jiang Y , Zhou X et al. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget 7(31), 50624–50634 (2016).
   PubMedGoogle Scholar
• Li C , Zhao S , Zheng Y et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur. J. Cancer 144, 232–241 (2021).
   PubMed Web of Science ®Google Scholar
• Shang X , Zhao G , Liang F et al. Safety and effectiveness of pembrolizumab combined with paclitaxel and cisplatin as neoadjuvant therapy followed by surgery for locally advanced resectable (stage III) esophageal squamous cell carcinoma: a study protocol for a prospective, single-arm, single-center, open-label, phase-II trial (Keystone-001). Ann. Transl. Med. 10(4), 229 (2022).
   PubMed Web of Science ®Google Scholar
• Li Z , Liu J , Zhang M et al. A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): interim results. J. Clin. Oncol. 39(Suppl. 15), Abstract 4060 (2021).
   Web of Science ®Google Scholar
• Gu Y , Chen X , Wang D et al. A study of neoadjuvant sintilimab combined with triplet chemotherapy of lipo-paclitaxel, cisplatin, and S-1 for resectable esophageal squamous cell carcinoma (ESCC). Ann. Oncol. 31(Suppl. 6), S1287–S1318 (2020).
   PubMedGoogle Scholar
• Zhao L , Xing W , Yang Y et al. The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: a phase II study. J. Clin. Oncol. 39(Suppl. 15), Abstract 4051 (2021).
   Google Scholar
• Yan X , Duan H , Ni Y et al. Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: a prospective, single-arm, phase II study (TD-NICE). Int. J. Surg. 103, 106680 (2022).
   PubMed Web of Science ®Google Scholar
• van den Ende T , de Clercq NC , van Berge Henegouwen MI et al. A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: the PERFECT trial. J. Clin. Oncol. 37(Suppl.), Abstract 4045 (2019).
   Google Scholar
• Kelly RJ , Smith KN , Anagnostou V et al. Neoadjuvant nivolumab plus concurrent chemoradiation in stage II/III esophageal/gastroesophageal junction cancer. J. Clin. Oncol. 37(Suppl. 4), Abstract 142 (2019).
   Web of Science ®Google Scholar
• Jiang N , Jiang M , Zhu X et al. SCALE-1: safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus. J. Clin. Oncol. 40(Suppl. 16), Abstract 4063 (2022).
   Web of Science ®Google Scholar
• Cowzer D , Wu AJC , Sihag S et al. Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: final results. J. Clin. Oncol. 40(Suppl. 16), Abstract 4029 (2022).
   Web of Science ®Google Scholar
• Uboha NV , Eickhoff JC , Maloney JD et al. Phase I/II trial of perioperative avelumab in combination with chemoradiation (CRT) in the treatment of stage II/III resectable esophageal and gastroesophageal junction (E/GEJ) cancer. J. Clin. Oncol. 40(Suppl. 16), Abstract 4034 (2022).
   Web of Science ®Google Scholar
• Shang X , Zhang W , Zhao G et al. Pembrolizumab combined with neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy followed by surgery for locally advanced oesophageal squamous cell carcinoma: protocol for a multicentre, prospective, randomized-controlled, phase III clinical study (Keystone-002). Front. Oncol. 12, 831345 (2022).
   PubMedGoogle Scholar
• Yang Y , Zhu L , Cheng Y et al. Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study). BMC Cancer 22(1), 506 (2022).
   PubMed Web of Science ®Google Scholar
• Liu J , Li J , Lin W et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): a multicenter, phase 2 study. Int. J. Cancer 151, 128 (2022).
   PubMed Web of Science ®Google Scholar
• Duan H , Wang T , Luo Z et al. A multicenter single-arm trial of sintilimab in combination with chemotherapy for neoadjuvant treatment of resectable esophageal cancer (SIN-ICE study). Ann. Transl. Med. 9(22), 1700 (2021).
   PubMed Web of Science ®Google Scholar
• Hong ZN , Gao L , Weng K et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score matching analysis. Front. Immunol. 13, 836338 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang Z , Hong ZN , Xie S et al. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann. Transl. Med. 9, 16–23 (2021).
   PubMed Web of Science ®Google Scholar
• Lv H , Huang C , Li J et al. The survival outcomes of neoadjuvant sintilimab combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma. Front. Immunol. 13, 1100750 (2023).
   PubMed Web of Science ®Google Scholar
• Sihag S , Ku GY , Tan KS et al. Safety and feasibility of esophagectomy following combined immunotherapy and chemoradiotherapy for esophageal cancer. J. Thorac. Cardiovasc. Surg. 161, 836–843; e1 (2021).
   PubMedGoogle Scholar
• Zhang W , Li Y , Xue L et al. Encouraging pathological complete response rate from neoadjuvant chemotherapy with albumin-bound paclitaxel plus cisplatin and capecitabine for locally advanced esophageal squamous carcinoma: preliminary outcome of a retrospective study. Cancer Manag. Res. 13, 2163–2170 (2021).
   PubMed Web of Science ®Google Scholar
• Matsuda S , Kitagawa Y , Takemura R et al. Real-world evaluation of the efficacy of neoadjuvant DCF over CF in esophageal squa-mous cell carcinoma: propensity score matched analysis from 85 authorized Institutes for Esophageal Cancer in Japan. Ann. Surg. 278, e35–e42 (2022).
   PubMed Web of Science ®Google Scholar